Purdue University scientists have developed a method for stacking synthetic DNA and carbon nanotubes onto a biosensor electrode, a development that may lead to more accurate measurements for research related to diabetes and other diseases.
Standard sensors employ metal electrodes coated with enzymes that react with compounds and produce an electrical signal that can be measured. But the inefficiency of those sensors leads to imperfect measurements.
Carbon nanotubes, cylindrically shaped carbon molecules known to have excellent thermal and electrical properties, have been seen as a possibility for improving sensor performance. The problem is that the materials are not fully compatible with water, which limits their application in biological fluids.
Their findings, reported in the journal The Analyst, describe a sensor that essentially builds itself.
“In the future, we will be able to create a DNA sequence that is complementary to the carbon nanotubes and is compatible with specific biosensor enzymes for the many different compounds we want to measure,” Porterfield said. “It will be a self-assembling platform for biosensors at the biomolecular level.”
Choi developed a synthetic DNA that will attach to the surface of the carbon nanotubes and make them more water-soluble.
“Once the carbon nanotubes are in a solution, you only have to place the electrode into the solution and charge it. The carbon nanotubes will then coat the surface,” Choi said.
The electrode coated with carbon nanotubes will attract the enzymes to finish the sensor’s assembly.
The sensor described in the findings was designed for glucose. But Porterfield said it could be easily adapted for various compounds.
“You could mass produce these sensors for diabetes, for example, for insulin management for diabetic patients,” Porterfield said.
Porterfield said it may one day be possible to develop other sensors using this technology that could lead to more personalized medicines that could test in real time the effectiveness of drugs on their targets as with cancer patients.